⁃ Subjects who meet the following criteria will be eligible to participate in the study:

⁃ Healthy and IPF Subjects

• Female subjects and male subjects with female partners of child-bearing potential must agree to use adequate contraception (2 forms of birth control, one of which must be a barrier method). This criterion must be followed from the time of the first dose of treatment.

• Able to understand, sign the written informed consent form, and follow the study procedures.

• With no clinically significant abnormalities in vital signs, 12-lead ECG, and clinical laboratory assessments at screening as judged by the Investigator

• Corrected QT interval using Fridericia's (QTcF) \< 450 milliseconds (msec).

⁃ Healthy Subjects only

• Aged between 20 and 55 years of age inclusive, at the time of signing the informed consent.

• Alanine aminotransferase (ALT), alkaline phosphatase (ALP), and bilirubin ≤ 1.5x upper limit of normal (ULN) (isolated bilirubin \> 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%).

• Body weight ≥ 50 kilogram (kg), \< 75 kg and body mass index (BMI) within the range 19.0 - 29.9 kg/m2 (inclusive).

⁃ IPF Subjects only

• Aged between 40 and 90 years of age inclusive, at the time of signing the informed consent.

• FVC≥ 40% and DLCO≥30%

• Alanine aminotransferase (ALT), alkaline phosphatase (ALP), and bilirubin ≤ 2x upper limit of normal (ULN) (isolated bilirubin \> 2xULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%).

• Diagnosis of IPF as defined by ATS/ERS/JRS/ALAT guidelines (Raghu 2018) within the past 7 years prior to study participation.

• Patients who are ineffective with an approved therapy (i.e., pirfenidone or nintedanib), or who are judged by the Investigator to be unsuitable for receiving approved therapy